SAN DIEGO, Feb. 7 /PRNewswire-FirstCall/ —ACADIA Pharmaceuticals Inc.(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments for centralnervous system disorders, today announced that Uli Hacksell, Ph.D., ChiefExecutive Officer, will present at the BIO CEO & Investor Conference 2006 onTuesday, February 14, 2006, at 12:00 p.m. Eastern Time at the Waldorf=AstoriaHotel in New York City.
A live webcast of ACADIA's presentation will be accessible on thecompany's website, www.acadia-pharm.com, under the investors section and anarchived recording will be available on the website through February 28, 2006.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments for CNSdisorders. ACADIA currently has four drug programs in clinical development aswell as a portfolio of preclinical and discovery assets directed at largeunmet medical needs, including schizophrenia, Parkinson's disease, neuropathicpain, and glaucoma. All of the drug candidates in ACADIA's product pipelineemanate from discoveries made using its proprietary drug discovery platform.ACADIA's corporate headquarters is located in San Diego, California and itmaintains research and development operations in both San Diego and Malmo,Sweden.
Contacts:
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer
(858) 558-2871